VA-DXC-TECHNOLOGY
15.9.2021 10:02:09 CEST | Business Wire | Press release
DXC Technology (NYSE: DXC) and Lenovo today announced a collaboration with visionary robotics scientist Dr. Peter Scott-Morgan and his philanthropic foundation to develop ambitious assistive technology solutions by integrating the latest hardware, software, and artificial intelligence (AI) technologies to empower people with disabilities, illnesses, and other challenging conditions.
Scott-Morgan, known as the “world’s first human cyborg", is pushing technology to extend and enrich lives. He was diagnosed with motor neuron disease (MND) – also known as amyotrophic lateral sclerosis (ALS) – in 2017. When the first symptoms emerged, Scott-Morgan began exploring ways to upend the typical disease progression through his belief in the limitless potential of technology. Scott-Morgan’s vision is to: “Make the vulnerable safe, the powerless strong, the unfulfilled thrive.”
“The bedrock of our collaboration is a belief in the untapped potential of technology to unleash your dreams - whatever you are, whatever your background, whatever your circumstances, whatever your ambitions,” Scott-Morgan said. Initially told by doctors he had only two years to live, Scott-Morgan has a mantra: “Add hope with AI and Robotics!”
DXC and Lenovo – alongside a team of volunteers and leading technologists – will provide hardware, software support, integration, and artificial intelligence expertise. Key initiatives include:
- Developing autonomous, self-driving wheelchairs to navigate homes and beyond;
- Preserving personality with an avatar that renders quickly in photo-realistic detail;
- Leveraging augmented reality (AR) as a user interface controlled with only eye movements;
- Accelerating the generation and customization of emotionally expressive digital voices; and
- Embedding smart technology throughout a family home to enhance the life of all its occupants.
In addition to developing custom solutions, Lenovo has donated computing equipment for Scott-Morgan’s home-office. Calvin Crosslin, Lenovo’s Chief Diversity Officer and President of the Lenovo Foundation said: “We have a responsibility to make powerful technology as accessible as possible and create new opportunities. This is precisely why we rally behind the idea of smarter technology for all, and I am grateful to Dr. Scott-Morgan for inviting us to collaborate and share some small part of his extraordinary vision.”
DXC will act as technology integrator. Deploying capabilities from the Enterprise Technology Stack, DXC will bring technology know-how and experience to ensure seamless and secure integration across infrastructure, applications, analytics, and engineering solutions.
“Peter is an astonishing inspiration,” said Steve Turpie, President, EMEA at DXC. “The DXC team will offer consulting and support to define requirements, the target architecture, and the technology roadmap. Specifically, they will enable the functions for eye tracking, virtual keyboards, speech, and avatar performance. Peter, with the Foundation, has a tireless passion to challenge our thinking on how technology can be used to enhance people’s lives and society.”
Learn more about Dr. Peter Scott-Morgan, including his background, ongoing research, and opportunities to get involved through The Scott-Morgan Foundation .
“I applied a lifetime of research to rewrite my own future - an extraordinarily lucky break! But far more important, we’ve now the chance to rewrite the future for millions - eventually billions - by applying the lessons learned to make the vulnerable safe, the powerless strong, the unfulfilled thrive. I wanted a way to break free of my suddenly inadequate body, to overcome a devastating diagnosis and reimagine what ‘terminal disease’ could mean. But we can help everyone who feels disadvantaged. They can rise like a phoenix! With extraordinary support from my husband Francis, countless kind and brilliant collaborators, and technology leaders like DXC and Lenovo, I find the once-dark future incredibly bright.”
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. The world’s largest companies and public sector organizations trust DXC to deploy services across the Enterprise Technology Stack to drive new levels of performance, competitiveness, and customer experience. Learn more about how we deliver excellence for our customers and colleagues at DXC.com .
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services, and software) millions of customers every day and together create a more inclusive, trustworthy, and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub .
About Lenovo Tech World 2021 and Dr Peter Scott-Morgan
Scott-Morgan joined Lenovo at its Tech World 2021 event on September 8 to speak with Thorsten Stremlau, Lenovo’s director of strategic enterprise consulting, about their shared goals of delivering smarter technology for all.
“I am deeply humbled to work with Peter, an absolutely brilliant scientist and inspiring human,” said Stremlau, who is leading Lenovo’s efforts. “We focus a lot on increasing accessibility and diversity at Lenovo , and this is a singular opportunity to ensure our innovation makes a real difference – for both Peter and, I hope, many others.”
About other partners supporting The Scott-Morgan Foundation
Other key collaborators already working with Scott-Morgan on this initiative include Matthew Aylett of CereProc, Amanda Darby of Optimize3D at Pinewood Studios, and Ari Shapiro of Embody Digital.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005415/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom